RIPGBM is a brain-penetrant, orally available, glioblastoma multiforme (GBM) cancer stem cells (CSCs)-selective apoptosis inducer (GBM-1/-5/-39 EC50 = 220/290/890 nM; human neural progenitor cells (NPCs)/astrocytes/lung fibroblasts EC50 = 1.7/2.8/3.5 µM) with in vivo efficacy against intracranial human GBM orthotopic xenograft tumor growth in mice (50 mg/kg bid. po.). RIPGBM undergoes a cell type-selective metabolic redox conversion to preferentially form in GBM CSCs the derivative cRIPGBM that binds receptor-interacting protein kinase 2 (RIPK2, RIP2) and promotes the formation of a proapoptotic RIPK2/caspase-1 complex.